JP2022172276A5 - - Google Patents

Download PDF

Info

Publication number
JP2022172276A5
JP2022172276A5 JP2022139889A JP2022139889A JP2022172276A5 JP 2022172276 A5 JP2022172276 A5 JP 2022172276A5 JP 2022139889 A JP2022139889 A JP 2022139889A JP 2022139889 A JP2022139889 A JP 2022139889A JP 2022172276 A5 JP2022172276 A5 JP 2022172276A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022139889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022172276A (ja
JP7840234B2 (ja
Filing date
Publication date
Priority claimed from JP2021151709A external-priority patent/JP7147030B2/ja
Application filed filed Critical
Publication of JP2022172276A publication Critical patent/JP2022172276A/ja
Publication of JP2022172276A5 publication Critical patent/JP2022172276A5/ja
Application granted granted Critical
Publication of JP7840234B2 publication Critical patent/JP7840234B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022139889A 2020-09-18 2022-09-02 抗hla-dq2.5抗体およびセリアック病の治療のためのその使用 Active JP7840234B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020157873 2020-09-18
JP2020157873 2020-09-18
JP2021151709A JP7147030B2 (ja) 2020-09-18 2021-09-17 抗hla-dq2.5抗体およびセリアック病の治療のためのその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021151709A Division JP7147030B2 (ja) 2020-09-18 2021-09-17 抗hla-dq2.5抗体およびセリアック病の治療のためのその使用

Publications (3)

Publication Number Publication Date
JP2022172276A JP2022172276A (ja) 2022-11-15
JP2022172276A5 true JP2022172276A5 (https=) 2024-09-26
JP7840234B2 JP7840234B2 (ja) 2026-04-03

Family

ID=80739984

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021151709A Active JP7147030B2 (ja) 2020-09-18 2021-09-17 抗hla-dq2.5抗体およびセリアック病の治療のためのその使用
JP2022139889A Active JP7840234B2 (ja) 2020-09-18 2022-09-02 抗hla-dq2.5抗体およびセリアック病の治療のためのその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021151709A Active JP7147030B2 (ja) 2020-09-18 2021-09-17 抗hla-dq2.5抗体およびセリアック病の治療のためのその使用

Country Status (16)

Country Link
US (2) US11739153B2 (https=)
EP (1) EP4214236A4 (https=)
JP (2) JP7147030B2 (https=)
KR (2) KR20230116942A (https=)
CN (3) CN116096757B (https=)
AR (1) AR123537A1 (https=)
AU (2) AU2021343008B2 (https=)
CA (1) CA3192661A1 (https=)
CL (1) CL2023000765A1 (https=)
CO (1) CO2023003681A2 (https=)
CR (1) CR20230166A (https=)
IL (1) IL301326A (https=)
MX (1) MX2023002191A (https=)
PE (1) PE20231208A1 (https=)
TW (2) TWI820484B (https=)
WO (1) WO2022059766A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020204054A1 (en) * 2019-04-01 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5 antibody
KR20230116942A (ko) * 2020-09-18 2023-08-04 추가이 세이야쿠 가부시키가이샤 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의사용
KR102614250B1 (ko) * 2021-10-08 2023-12-15 추가이 세이야쿠 가부시키가이샤 항hla-dq2.5 항체의 제제
EP4413998A4 (en) * 2021-10-08 2026-02-25 Chugai Pharmaceutical Co Ltd METHOD FOR PREPARING A PRE-FILLED SYRINGE FORMULATION
WO2026022921A1 (ja) * 2024-07-23 2026-01-29 中外製薬株式会社 抗体の製造方法
WO2026044027A1 (en) * 2024-08-20 2026-02-26 Victor Raso Major histocompatibility complex peptides as therapeutic targets for autoimmune diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
CA2443886A1 (en) 2001-04-12 2002-10-24 Academisch Ziekenhuis Leiden Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
AU2009210741A1 (en) 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
AU2013204429B9 (en) 2008-11-30 2017-01-05 Immusant, Inc. Compositions and methods for treatment of celiac disease
EP2437780B1 (en) 2009-06-04 2016-03-23 The Regents of the University of Colorado Therapeutic compositions and methods for the prevention of autoimmune diseases
JP2013541937A (ja) 2010-08-05 2013-11-21 エフ.ホフマン−ラ ロシュ アーゲー 抗mhc抗体−抗ウイルス性サイトカイン融合タンパク質
CN109134658B (zh) * 2011-10-31 2022-10-14 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
WO2016202805A2 (en) 2015-06-15 2016-12-22 Consejo Superior De Investigaciones Científicas (Csic) Targeting of prolamin by rnai in bread wheat
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
US20200040085A1 (en) * 2017-02-27 2020-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5/8 antibody and its use for the treatment of celiac disease
CN117777294A (zh) 2017-10-03 2024-03-29 中外制药株式会社 抗hla-dq2.5抗体
GB201802338D0 (en) * 2018-02-13 2018-03-28 Univ Oslo Antigen binding proteins
WO2020204054A1 (en) * 2019-04-01 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5 antibody
KR20230116942A (ko) 2020-09-18 2023-08-04 추가이 세이야쿠 가부시키가이샤 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의사용

Similar Documents

Publication Publication Date Title
JP2022068302A5 (https=)
JP2024023385A5 (https=)
JP2022028828A5 (https=)
JP2022025124A5 (https=)
JP2021185136A5 (https=)
JP2021169491A5 (https=)
JP2024059739A5 (https=)
JP2023022224A5 (https=)
JP2024016014A5 (https=)
JP2021038271A5 (https=)
JP2022060295A5 (https=)
JP2023100643A5 (https=)
JP2025506484A5 (https=)
JP2022537813A5 (https=)
JP2020171301A5 (https=)
JP2020120660A5 (https=)
JP2024112817A5 (https=)
JP2025084837A5 (https=)
JP2023011759A5 (https=)
JP2023085551A5 (https=)
JP2024534771A5 (https=)
JP2022022379A5 (https=)
JP2022172276A5 (https=)
JP2020141705A5 (https=)
JP2024063214A5 (https=)